Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Open access
Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.·2020·Journal for ImmunoTherapy of Cancer

Abstract

As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor as standard of care or in an investigational study. However, because of the kinetics and patterns of response to PD-1/PD-L1 blockade, and the lack of consistency in the clinical definitions of resistance to therapy, the design of clinical trials of new agents and interpretation of results remains an important challenge. To address this unmet need, the Society for Immunotherapy of Cancer convened a multistakeholder taskforce—consisting of experts in cancer immunotherapy from academia, industry, and government—to generate consensus clinical definitions for resistance to PD-(L)1 inhibitors in three distinct scenarios: primary resistance, secondary resistance, and progression after treatment discontinuation. The taskforce generated consensus on several key issues such as the timeframes that delineate each type of resistance, the necessity for confirmatory scans, and identified caveats for each specific resistance classification. The goal of this effort is to provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2019-000398

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 291

Metadata

Authors
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., Gulley, J. L., Gupta, S., Humphrey, R. W., LaVallee, T. M., Le, D. T., Hubbard-Lucey, V. M., Papadimitrakopoulou, V. A., Postow, M. A., Rubin, E. H., Sharon, E., Taube, J. M., Topalian, S. L., Zappasodi, R., Sznol, M., & Sullivan, R. J.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-03
Volume
8
Issue
1
Pages
e000398
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3014748351
Cited by
291
References
11
FWCI
10.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. https://app.cochat.ai/papers/10.1136/jitc-2019-000398
The paper
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., Gulley, J. L., Gupta, S., Humphrey, R. W., LaVallee, T. M., Le, D. T., Hubbard-Lucey, V. M., Papadimitrakopoulou, V. A., Postow, M. A., Rubin, E. H., . . . Sullivan, R. J. (2020). Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2019-000398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.